Otolith Labs

Otolith Labs is a privately-held, pre-revenue biotech company pioneering a novel, non-pharmacological treatment for chronic vertigo. Its core innovation is a headworn wearable that uses patented bone conduction signals (nVRT) to interact with the inner ear's vestibular system, aiming to provide immediate symptom relief. Backed by FDA Breakthrough Device Designation and over $20M in funding from investors including Mark Cuban, the company is conducting clinical studies to support a De Novo FDA submission. Otolith addresses a significant unmet need in a large patient population with limited treatment options.

Patented non-invasive Vestibular Resonance Therapy (nVRT), a bone conduction technology delivering precise mechanical signals to interact with the inner ear's vestibular system.

The competitive landscape for a dedicated, non-invasive wearable vertigo treatment is currently sparse, positioning Otolith's device as potentially first-in-class. It competes indirectly with existing standards of care: vestibular rehabilitation therapy (requiring clinical visits), off-label medications (with side-effect burdens), and invasive surgeries. Competition may emerge from other neurostimulation or device companies targeting the vestibular system.